339
Views
16
CrossRef citations to date
0
Altmetric
Psoriasis

Clinical symptoms and self-reported disease severity among patients with psoriasis – Implications for psoriasis management

, , , &
Pages 514-519 | Received 16 Jan 2015, Accepted 13 Mar 2015, Published online: 17 Apr 2015

References

  • Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–96
  • Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9
  • Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–23
  • American Academy of Dermatology. Psoriasis is more than skin deep. ScienceDaily [internet], 2010 March 06. Available from http://www.sciencedaily.com/releases/2010/03/100306104436.htm. Accessed December 16, 2014
  • Sampogna F, Gisondi P, Melchi CF, et al; IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151:594–9
  • Bilac C, Ermertcan AT, Bilac DB, et al. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75:551
  • Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract. 2002;8:367–76
  • Zamirska A, Reich A, Berny-Moreno J, et al. Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol. 2008;88:132–5
  • Szepietowski JC, Reich A, Wisnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat. 2002;10:221–6
  • Sampogna F, Tabolli S, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol. 2007;157:508–13
  • Melzack R, Katz J. Pain measurement in adult patients. Wall & Melzack’s Textbook of Pain. 6th ed. [Ebook]. Philadelphia, PA: Elsevier/Churchill Livingstone, 2006
  • Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062
  • Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000–6
  • Kimball AB, Gladman D, Gelfand JM, et al; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031–42
  • Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.e1–e13
  • Gelfand JM, Dommasch Ed, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411–18
  • Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol. 2012;167:1345–50
  • Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148:995–1000
  • Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24–8
  • Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey: 2003–2006. Arch Dermatol. 2011;147:419–24
  • Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654–62
  • Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–8
  • Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216:152–5
  • Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778–86
  • Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758–64
  • Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–92
  • Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5
  • Shutty BG, West C, Huang KE, et al. Sleep disturbances in psoriasis. Dermatol Online J. 2013;19:1
  • Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4
  • Baker CS, Foley PA, Braue A. Psoriasis uncovered – measuring burden of disease impact in a survey of Australians with psoriasis. Australas J Dermatol. 2013;54(Suppl):1–6
  • Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157–63
  • Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20:1929–36
  • Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major diseases. J Am Acad Dermatol. 1999;41:401–7
  • Ljosaa TM, Stubhaug A, Mörk C, et al. Improvement in Psoriasis Area and Severity Index score predicts improvement in skin pain over time in patients with psoriasis. Acta Derm Venereol. 2013;93:330–4
  • Gupta MA, Gupta AK, Kirkby S, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol. 1988;124:1052–7
  • Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity. A population-based study. JAMA Dermatol. 2013;149:1173–9
  • Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7:e52935
  • Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205
  • Kantar Health. The psoriasis market: syndicated patient study report 2013 – Wave 5 [US]. Princeton, NJ, 2013
  • Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica. 1978;157:238–44
  • Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9
  • Reich A, Hrehorow E, Szepietowski C. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257–63
  • Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73
  • Zachariae R, Lei U, Haedersdal M, et al. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the Itch Severity Scale. Acta Derm Venereol. 2012;92:508–14
  • Feldman SR, Fleischer AB, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106:183–6
  • Sampogna F, Sera F, Mazzotti E, et al. Performance of the self-administered Psoriasis Area and Severity Index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol. 2003;139:353–8
  • Raphael K. Recall bias: a proposal for assessment and control. Int J Epidemiol. 1987;16:167–70
  • Hassan E. Recall bias can be a threat to retrospective and prospective research designs. Internet J Epidemiol [internet]. Available from http://ispub.com/IJE/3/2/13060. Accessed December 8, 2014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.